



UCCH Pathway

UCCH Guideline Basal Cell Carcinoma

2.03.01 Anlage 40
Version March 2022

Guideline Basal Cell Carcinoma (S2k-Leitlinie Basalzellkarzinom der Haut), 16th August 2018
Version 03, Mar/2022
according to TNM classification of the AJCC 2017 (8th edition)

Basal Cell Carcinoma board members:

C. Gebhardt, M. Christolouka, S.W. Schneider, N. Booken, L. Hildebrandt (Dermatology)

T. Haalck (Dermatology, MVZ)

M. Fischer (Dermatology, BWK)

W. Fiedler (Med. Oncology)

A. Krüll (Radiooncology)

U. Göbel (patient representative UCCH)

Responsible author	L. Hildebrandt (Dermatology)
Implemented	Jan/2020
Revised	Mar/2020, Mar/2022
Next planned review	Mar/2024

Legend of Colours



= Therapeutic procedure



= Clinical or diagnostic condition



= Diagnostic procedure



= Clinical trial




= Supportive measure



= Referral



= Tumorboard
(including post
tumorboard interaction
with patient that follows
the principles of shared
decision-making)




¹ Basal cell carcinoma risk factors: UV exposure, genetic predisposition, immunosuppression, chronic arsenic exposure, ionising radiation

² High risk of relapse: clinical diameter >6mm (central face, hands and feet, genitals) >10mm (beside central face, tibial) >20mm (rest); relapse, located on radioderm, perineural invasion, subtype (sklerodermiform, infiltrating, metatypical, micro nodular)


Pathway page 2: Carcinoma in situ or $\leq 2\text{mm}$ tumor thickness with low risk of relapse




Pathway page 2: $>2\text{mm}$ tumor thickness with low risk of relapse



Pathway page 2: High risk of relapse




Pathway page 3: Stage III-IV with positive nodes, locally-advanced BCC



³ Not meaningful resectable as consented in an interdisciplinary tumorboard

Pathway page 4: Primary Therapy Stage IV with distant metastases



³ Not meaningful resectable as consented in an interdisciplinary tumorboard

Page 5: Follow-up

